巴基斯坦羟氯喹、奥司他韦和阿奇霉素治疗无合并症新诊断COVID-19患者的随机对照试验方案摘要
该研究为在巴基斯坦开展的多中心、多臂、适应性随机对照试验,评估羟氯喹、奥司他韦和阿奇霉素单用及联合治疗无合并症新诊断COVID-19患者的疗效。主要结局为第7天qRT-PCR转阴和临床改善。截至2020年7月3日已招募约470名参与者。
要点
- 比较三种药物单用及联合共7组方案对病毒清除和临床改善的效果。
- 主要结局为第7天qRT-PCR转阴和7分类序贯量表改善2分。
- 采用适应性设计,样本量由数据安全监查委员会定期审查确定。
核心结论
- 该试验旨在评估羟氯喹、奥司他韦和阿奇霉素单用及联合治疗无合并症COVID-19患者的有效性。
研究设计与样本
- 多中心、多臂、多阶段、平行设计的适应性随机对照试验,嵌套于综合队列研究。
- 计划纳入无合并症或慢性病控制良好的新诊断COVID-19患者,来自巴基斯坦8个城市的12个中心。
- 排除孕妇、哺乳期妇女、严重呼吸困难、已接受治疗及严重合并症患者。
- 随机化采用计算机生成的区组随机数列表,分配隐藏,各组分配比例1:1。
- 开放标签设计,医生和参与者均不设盲。
关键数值与推荐
- 羟氯喹磷酸盐/硫酸盐200 mg口服,每8小时一次,每日三次,共5天。
- 奥司他韦75 mg口服,每日两次,共5天。
- 阿奇霉素第1天500 mg口服每日一次,第2-5天250 mg口服每日两次。
- 主要实验室结局为第7天qRT-PCR转阴。
- 主要临床结局为第7天7分类序贯量表较基线改善2分。
临床怎么用
- 该方案为COVID-19早期治疗提供多种药物组合的疗效比较证据。
- 适应性设计允许根据中期数据调整试验方案。
局限性
- 开放标签设计可能引入偏倚。
- 样本量未预先固定,由数据安全监查委员会定期审查确定。
- 试验针对无合并症患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes). TRIAL DESIGN: An adaptive design, set within a comprehensive cohort study, to permit flexibility in this fast-changing clinical and public health scenario. The randomized study will be a multicenter, multiarm, multistage, randomized controlled trial with a parallel design. An observation only cohort will emerge from those not consenting to randomization. PARTICIPANTS: Eligible will be newly diagnosed patients, either hospitalized or in self-isolation, without any comorbidities or with controlled chronic medical conditions like diabetes mellitus and hypertension. Participants of any gender or age group having tested positive for COVID-19 on Real-Time qRT-PCR (Quantitative Reverse Transcription PCR) will be invited to take part in study at twelve centers across eight cities in Pakistan. Those pregnant or lactating, severely dyspneic or with respiratory distress, already undergoing treatment, and with serious comorbidities like liver or kidney failure will be excluded. INTERVENTION AND COMPARATOR: There will be a total of seven comparator groups: Each drug (Hydroxychloroquine Phosphate/Sulfate, Oseltamivir and Azithromycin) given as monotherapy (three groups); combinations of each of two drugs (three groups); and a final group on triple drug regimen. MAIN OUTCOMES: The laboratory-based primary outcome will be turning the test negative for COVID-19 on qRT-PCR on day 7 of follow-up. The clinical primary outcome will be improvement from baseline of two points on a seven-category ordinal scale of clinical status on day 7 of follow-up. RANDOMIZATION: Participants will be randomized, maintaining concealment of allocation sequence, using a computer-generated random number list of variable block size into multiple intervention groups in the allocation ratio of 1:1 for all groups. BLINDING (MASKING): This is an open label study, neither physician nor participants will be blinded. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): This is an adaptive design and parameters for formal sample size calculation in a new disease of a previously unknown virus are not available. Thus, the final sample size will be subjected to periodic reviews at each stage of adaptive design and subsequent advice of National Data Safety & Management Board (NDSMB) notified by Drug Regulatory Authority of Pakistan. TRIAL STATUS: Protocol Version 1.7 dated July 5, 2020. By July 03, 2020, the trial had recruited a total of about 470 participants across 12 centers after approval from the National Bioethics Committee and Drug Regulatory Authority of Pakistan. Recruitment started on April 20, 2020. The recruitment is expected to continue for at least three months subject to review by the National Data Safety and Management Board (NDSMB) notified by Drug Regulatory Authority of Pakistan. TRIAL REGISTRATION: Prospectively registered on 8 April 2020 at clinicaltrials.gov ID: NCT04338698 The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file2).
引用
- Akram J, Azhar S, Shahzad M, et al. Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32771032. doi:10.1186/s13063-020-04616-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。